Matinas BioPharma Holdings Inc is a US-based clinical-stage biopharmaceutical company which focuses on developing anti-infectives for orphan indications. The company's lead product candidate MAT2203 is an orally-administered cochleate formulation of a broad spectrum anti-fungal drug called amphotericin B and other clinical stage product candidate is MAT2501 which is a an orally administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic amikacin which treats different types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections as well as various multidrug-resistant gram negative and intracellular bacterial infections.